Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)-positive tumor phenotype. Methods: A dosimetry estimate was calculated on the ba...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 1, 2017
|
| In: |
Journal of nuclear medicine
Year: 2017, Jahrgang: 58, Heft: 10, Pages: 1624-1631 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.117.191395 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.2967/jnumed.117.191395 Verlag, Volltext: http://jnm.snmjournals.org/content/58/10/1624 
|
| Verfasserangaben: | Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederik L. Giesel, and Alfred Morgenstern |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1583693424 | ||
| 003 | DE-627 | ||
| 005 | 20230427193408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181114s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.117.191395 |2 doi | |
| 035 | |a (DE-627)1583693424 | ||
| 035 | |a (DE-576)513693424 | ||
| 035 | |a (DE-599)BSZ513693424 | ||
| 035 | |a (OCoLC)1341023528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 245 | 1 | 0 | |a Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617 |b dosimetry estimate and empiric dose finding |c Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederik L. Giesel, and Alfred Morgenstern |
| 246 | 3 | 3 | |a 225 Ac-PSMA-617 |
| 264 | 1 | |c October 1, 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2018 | ||
| 500 | |a Im Titel ist die 225 in 225Ac-PSMA-617 hochgestellt | ||
| 520 | |a The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)-positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time-activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response. | ||
| 650 | 4 | |a 225Ac | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a PSMA | |
| 650 | 4 | |a targeting | |
| 700 | 1 | |a Rathke, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1151445495 |0 (DE-627)1011715392 |0 (DE-576)497748223 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 58(2017), 10, Seite 1624-1631 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617 dosimetry estimate and empiric dose finding |
| 773 | 1 | 8 | |g volume:58 |g year:2017 |g number:10 |g pages:1624-1631 |g extent:8 |a Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617 dosimetry estimate and empiric dose finding |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.117.191395 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/58/10/1624 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181114 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 8 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 7 | ||
| 998 | |g 1151445495 |a Rathke, Hendrik |m 1151445495:Rathke, Hendrik |d 910000 |d 911400 |e 910000PR1151445495 |e 911400PR1151445495 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1583693424 |e 3032278015 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.2967/jnumed.117.191395"],"eki":["1583693424"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"note":["Gesehen am 13.12.2021"],"id":{"zdb":["2040222-3"],"issn":["2159-662X","1535-5667"],"eki":["325793603"]},"part":{"issue":"10","extent":"8","text":"58(2017), 10, Seite 1624-1631","volume":"58","pages":"1624-1631","year":"2017"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"JNM","title_sort":"Journal of nuclear medicine","title":"Journal of nuclear medicine"}],"name":{"displayForm":["Society of Nuclear Medicine"]},"origin":[{"publisher":"Soc.","dateIssuedDisp":"1964-","dateIssuedKey":"1964","publisherPlace":"New York, NY"}],"corporate":[{"role":"isb","display":"Society of Nuclear Medicine"}],"pubHistory":["Nachgewiesen 5.1964 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JNM"}],"language":["eng"],"disp":"Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617 dosimetry estimate and empiric dose findingJournal of nuclear medicine","recId":"325793603"}],"note":["Gesehen am 14.11.2018","Im Titel ist die 225 in 225Ac-PSMA-617 hochgestellt"],"recId":"1583693424","name":{"displayForm":["Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Marcus Bronzel, Christos Apostolidis, Wilko Weichert, Uwe Haberkorn, Frederik L. Giesel, and Alfred Morgenstern"]},"origin":[{"dateIssuedDisp":"October 1, 2017","dateIssuedKey":"2017"}],"person":[{"family":"Kratochwil","display":"Kratochwil, Clemens","given":"Clemens","role":"aut"},{"family":"Rathke","display":"Rathke, Hendrik","given":"Hendrik","role":"aut"},{"family":"Haberkorn","display":"Haberkorn, Uwe","given":"Uwe","role":"aut"},{"family":"Giesel","given":"Frederik L.","display":"Giesel, Frederik L.","role":"aut"}],"titleAlt":[{"title":"225 Ac-PSMA-617"}],"language":["eng"],"title":[{"title":"Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617","title_sort":"Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617","subtitle":"dosimetry estimate and empiric dose finding"}]} | ||
| SRT | |a KRATOCHWILTARGETEDTH1201 | ||